Bottom line
CMIRX vs AMCPX: the short answer
CMIRX (Conestoga Discovery Fund) and AMCPX (Amcap Fund) are both mutual funds.
But AMCPX is far broader, holding 121 positions to 29 for CMIRX, so beyond the top names it adds exposure CMIRX doesn't have.
AMCPX is cheaper at 0.64% vs 1.25% — a difference of $61 a year per $10,000 invested.
Over five years, AMCPX returned +9.2% a year vs −0.6% for CMIRX.
AMCPX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
CMIRX vs AMCPX side by side
| CMIRX | AMCPX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Conestoga | American Funds (Capital Group) |
| Category | Large Blend | Large Blend |
| Expense ratio | 1.25% | 0.64% |
| Annual cost per $10k | $125 | $64 |
| 10-yr cost on $10k (prospectus) | $6,151 | $1,327 |
| Max front load | — | 5.75% |
| 12b-1 fee | 0% | 0.24% |
| 1-yr return | +16.6% | +11.0% |
| 5-yr return (annualized) | −0.6% | +9.2% |
| 10-yr return (annualized) | — | +12.0% |
| Best quarter | — | +23.2% |
| Worst quarter | — | −19.5% |
| Net assets (fund) | $5.7M | $97.2B |
| Number of holdings | 29 | 121 |
| Portfolio turnover | 31% | 36% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
CMIRX and AMCPX share none of their top holdings.
CMIRX top 10
- Twist Bioscience Corp — 5.59%
- Mama's Creations Inc — 5.36%
- Vericel Corp — 5.04%
- Digi International Inc — 5.02%
- Transcat Inc — 4.47%
- Electrovaya Inc — 4.46%
- Graham Corp — 4.28%
- Biolife Solutions Inc — 4.23%
- Palomar Holdings Inc — 4.20%
- Cryoport Inc — 4.06%
AMCPX top 10
- Broadcom Inc — 7.58%
- Nvidia Corp — 7.04%
- Amazon.com Inc — 6.21%
- Alphabet Inc — 5.77%
- Microsoft Corp — 5.63%
- Eli Lilly And Co — 4.59%
- Meta Platforms Inc — 3.84%
- Taiwan Semiconductor Manufacturing Co Ltd — 3.36%
- Transdigm Group Inc — 2.29%
- Vertex Pharmaceuticals Inc — 2.14%
FAQ
What is the difference between CMIRX and AMCPX?
Which is cheaper, CMIRX or AMCPX?
Should I own both CMIRX and AMCPX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.